Researchers demonstrated CRISPR–Cas3 can generate long-range deletions at the TTR locus and substantially lower circulating transthyretin in mice, offering an alternative to Cas9 strategies for transthyretin amyloidosis. The team reported ~48.7% hepatic editing after a single lipid‑nanoparticle (LNP) dose and an ~80% drop in serum TTR in treated animals, with deletion lengths up to 21 kb in vivo. Separately, St. Jude Children’s Research Hospital released a new method to detect off‑target edits from base editors, aimed at improving safety assessments for precision genome editing. The assay addresses a key regulatory and translational gap by enabling more sensitive detection of small off‑target changes that could pose clinical risks. Together these developments advance both the therapeutic promise of alternative CRISPR systems and the tools needed to evaluate their safety, naming key actors (the Cas3 study team and St. Jude researchers) and reporting quantitative outcomes for industry assessment.